OBJECTIVES: To determine the costs for children with leukodystrophies and whether high costs are associated with characteristic clinical features or resources use. STUDY DESIGN: We determined health care costs in a population cohort of 122 patients with leukodystrophies, including inpatient, outpatient, and emergency department use, during a 9-year period. We analyzed differences in patients with high costs (>85th percentile) and their health care use. RESULTS: Patients with leukodystrophy had significant variability in resource use, with the top 15th percentile of patients accounting for 73% of costs ($9.6 million). The majority of costs, 81% ($10.8 million), arose from inpatient hospitalization. High-cost patients had more and longer hospitalizations, increased requirements for intensive unit care and mechanical ventilation, and significantly more infections. Importantly, bone marrow transplantation did not solely account for the difference between high-cost and low-cost groups. CONCLUSION: Inpatient hospitalization is the greatest source of health care resource use in patients with leukodystrophies. A minority of patients account for the majority of costs, primarily attributable to an increased volume of hospitalization. Strategies to improve care and reduce costs will need to reduce inpatient stays and target modifiable reasons for hospitalization.
OBJECTIVES: To determine the costs for children with leukodystrophies and whether high costs are associated with characteristic clinical features or resources use. STUDY DESIGN: We determined health care costs in a population cohort of 122 patients with leukodystrophies, including inpatient, outpatient, and emergency department use, during a 9-year period. We analyzed differences in patients with high costs (>85th percentile) and their health care use. RESULTS:Patients with leukodystrophy had significant variability in resource use, with the top 15th percentile of patients accounting for 73% of costs ($9.6 million). The majority of costs, 81% ($10.8 million), arose from inpatient hospitalization. High-cost patients had more and longer hospitalizations, increased requirements for intensive unit care and mechanical ventilation, and significantly more infections. Importantly, bone marrow transplantation did not solely account for the difference between high-cost and low-cost groups. CONCLUSION: Inpatient hospitalization is the greatest source of health care resource use in patients with leukodystrophies. A minority of patients account for the majority of costs, primarily attributable to an increased volume of hospitalization. Strategies to improve care and reduce costs will need to reduce inpatient stays and target modifiable reasons for hospitalization.
Authors: Stephan Harbarth; John P Burke; James F Lloyd; R Scott Evans; Stanley L Pestotnik; Matthew H Samore Journal: Clin Infect Dis Date: 2002-12-02 Impact factor: 9.079
Authors: Tara J Lemoine; Kathryn J Swoboda; Susan L Bratton; Richard Holubkov; Michael Mundorff; Rajendu Srivastava Journal: Pediatr Crit Care Med Date: 2012-05 Impact factor: 3.624
Authors: Minke H de Ru; Jaap J Boelens; Anibh M Das; Simon A Jones; Johanna H van der Lee; Nizar Mahlaoui; Eugen Mengel; Martin Offringa; Anne O'Meara; Rossella Parini; Attilio Rovelli; Karl-Walter Sykora; Vassili Valayannopoulos; Ashok Vellodi; Robert F Wynn; Frits A Wijburg Journal: Orphanet J Rare Dis Date: 2011-08-10 Impact factor: 4.123
Authors: Cameron J Brimley; Jonathan Lopez; Keith van Haren; Jacob Wilkes; Xiaoming Sheng; Clint Nelson; E Kent Korgenski; Rajendu Srivastava; Joshua L Bonkowsky Journal: Pediatr Neurol Date: 2013-09 Impact factor: 3.372
Authors: Jackson Richards; E Kent Korgenski; Ryan J Taft; Adeline Vanderver; Joshua L Bonkowsky Journal: Am J Med Genet A Date: 2015-07-16 Impact factor: 2.802
Authors: Francesco Gavazzi; Laura Adang; Amy Waldman; Amanda K Jan; Geraldine Liu; Scott A Lorch; Sara B DeMauro; Justine Shults; Samuel R Pierce; Elizabeth Ballance; Tracy Kornafel; Ann Harrington; Allan M Glanzman; Adeline Vanderver Journal: Pediatr Neurol Date: 2021-09-24 Impact factor: 4.210
Authors: Laura A Adang; Omar Sherbini; Laura Ball; Miriam Bloom; Anil Darbari; Hernan Amartino; Donna DiVito; Florian Eichler; Maria Escolar; Sarah H Evans; Ali Fatemi; Jamie Fraser; Leslie Hollowell; Nicole Jaffe; Christopher Joseph; Mary Karpinski; Stephanie Keller; Ryan Maddock; Edna Mancilla; Bruce McClary; Jana Mertz; Kiley Morgart; Thomas Langan; Richard Leventer; Sumit Parikh; Amy Pizzino; Erin Prange; Deborah L Renaud; William Rizzo; Jay Shapiro; Dean Suhr; Teryn Suhr; Davide Tonduti; Jacque Waggoner; Amy Waldman; Nicole I Wolf; Ayelet Zerem; Joshua L Bonkowsky; Genevieve Bernard; Keith van Haren; Adeline Vanderver Journal: Mol Genet Metab Date: 2017-08-20 Impact factor: 4.797
Authors: Rebecca Ahrens-Nicklas; Lars Schlotawa; Andrea Ballabio; Nicola Brunetti-Pierri; Mauricio De Castro; Thomas Dierks; Florian Eichler; Can Ficicioglu; Alan Finglas; Jutta Gaertner; Brian Kirmse; Joerg Klepper; Marcus Lee; Amber Olsen; Giancarlo Parenti; Arastoo Vossough; Adeline Vanderver; Laura A Adang Journal: Mol Genet Metab Date: 2018-01-31 Impact factor: 4.797
Authors: Celestine H Yeung Gregerson; Amanda V Bakian; Jacob Wilkes; Andrew J Knighton; Flory Nkoy; Matthew Sweney; Francis M Filloux; Joshua L Bonkowsky Journal: J Child Neurol Date: 2019-09-10 Impact factor: 1.987